Dr. Eddie Garon from UCLA Medical Center reviews the general mechanism of action of immune checkpoint inhibitors and how they can be an effective therapy in lung cancer.

Guest post by Dr. Nate Pennell, a board certified medical oncologist at the Taussig Cancer Center at the Cleveland Clinic. He specializes in the treatment of thoracic malignancies with a focus on lung cancer. Dr.

In January, 2015, the CheckMate 017 trial of the immune checkpoint inhibitor Opdivo (nivolumab) versus the standard chemo agent Taxotere (docetaxel) as second line therapy for patients with advanced squamous NSCLC was reported in a press release to be positive for a significant improvement in overall survival.

Immunotherapy Forum Video #26: Drs. Jared Weiss and Matthew Hellmann answer questions from the audience following their presentations on immunotherapy for lung cancer. Moderated by Dr. Jack West.

[powerpress]

Immunotherapy Forum Video #25: In Part 2 of 2 videos, Dr.

Immunotherapy Forum Video #24: In Part 1 of 2 videos, Dr.

Immunotherapy Forum Video #23: Dr. Jared Weiss highlights what doctors know about immunotherapy treatments for lung cancer.

In Part 2 of 2 videos about squamous lung cancer, Dr.

Acquired Resistance Forum Video #6: Dr. Nate Pennell of the Cleveland Clinic discussed the other options available to patients with ALK, ROS1 and EGFR lung cancer, such as chemotherapy, Avastin, and immunotherapy.

[powerpress]

Dr. Jack West, Dr. Julie Brahmer, and Dr. Ben Creelan discuss the excitement the medical community is feeling about immunotherapy for the treatment of lung cancer. February 2014

[powerpress]